European regulators have given ImpediMed CE mark approval for its Sozo bioimpedance spectroscopy platform, which uses the company's L-Dex lateral lymphedema assessment system for noninvasive measurement and monitoring of body composition and fluid status. The platform is designed to be used by patients recovering from a coronary artery disease-related event or those with fluid management problems, heart failure or end-stage renal disease.
ImpediMed's bioimpedance spectroscopy system gains EU approval
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.